Clinical Trials Browser

Phase 1 × trebananib × Clear all

Kidney Neoplasms, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms

NCT00807859 2022-11-08

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Phase 1 Completed

65 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT01555268 2022-09-13

Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia

Phase 1 Completed

24 enrolled

Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

NCT01331941 2017-11-06

A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function

Phase 1 Completed

35 enrolled

Genitourinary

Kidney Diseases, Renal Insufficiency

NCT00861419 2017-02-08

To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.

Phase 1 Completed

88 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT01538095 2016-10-03

Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors

Phase 1 Completed

37 enrolled

CNS

Central Nervous System Neoplasms

NCT01253681 2015-10-14

Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer

Phase 1 Completed

27 enrolled

Gynecologic

Carcinoma, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01548482 2015-10-06

Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Phase 1 Completed

21 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT02525536 2015-09-22

A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Trebananib (AMG 386 ) in Adult Japanese Participants With Advanced Solid Tumors

Phase 1 Completed

18 enrolled 38 charts

Tumor-Agnostic

Neoplasms

NCT01992341 2014-09-23

AMG 386 Drug-Drug Interaction Study With Paclitaxel

Phase 1 Completed

35 enrolled

Sarcoma

Carcinoma, Sarcoma

NCT00102830 2010-08-20

Study Evaluating AMG 386 in Adult Patients With Advanced Solid Tumors

Phase 1 Completed

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Clinical Trials

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia

A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function

To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.

Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors

Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer

Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Trebananib (AMG 386 ) in Adult Japanese Participants With Advanced Solid Tumors

AMG 386 Drug-Drug Interaction Study With Paclitaxel

Study Evaluating AMG 386 in Adult Patients With Advanced Solid Tumors